Oxra-S 5/50 Mg (Dapagliflozin/Sitagliptin)

Oxra‑S 5/50 Mg is a prescription oral antidiabetic medication formulated for the management of type 2 diabetes mellitus. It combines two well‑studied agents, dapagliflozin and sitagliptin, in a fixed‑dose combination that targets glucose control through complementary mechanisms. The product is manufactured by Sun Pharmaceutical Industries Ltd, a globally recognized pharmaceutical company with a strong track record in diabetes care. Each strip contains fifteen tablets, and the medication is packaged in strengths of 5 mg dapagliflozin and 50 mg sitagliptin, delivering a balanced therapeutic effect for patients requiring dual‑axis glycemic control.

What is Oxra‑S 5/50 Mg? It is a branded formulation that unites a sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor with a dipeptidyl peptidase‑4 (DPP‑4) inhibitor. Dapagliflozin facilitates renal glucose excretion, while sitagliptin enhances incretin hormone activity to stimulate insulin release and suppress glucagon secretion. The synergistic action of these two pathways provides more comprehensive glucose lowering than either agent alone. Clinically, Oxra‑S is prescribed alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who have not achieved target HbA1c levels with monotherapy. National Institutes of Health (NIH) supports the use of dual therapy for improved outcomes.

The uses and benefits of Oxra‑S extend beyond simple glucose reduction. By lowering blood glucose levels, the medication helps reduce the risk of diabetes‑related complications such as cardiovascular events, kidney disease, and neuropathy. The SGLT‑2 component has demonstrated cardiovascular safety and modest weight loss benefits, while the DPP‑4 component supports sustained glycemic control without a high incidence of hypoglycemia when used as monotherapy. Patients often experience improved post‑prandial glucose excursions and better overall metabolic profiles, contributing to enhanced quality of life when combined with appropriate lifestyle modifications.

How does Oxra‑S work? Dapagliflozin blocks the SGLT‑2 protein in the proximal renal tubule, preventing glucose reabsorption and promoting its elimination through urine. This mechanism lowers circulating glucose independent of insulin pathways, making it effective even in insulin‑resistant states. Sitagliptin, on the other hand, inhibits DPP‑4, an enzyme that degrades incretin hormones (GLP‑1 and GIP). By preserving these hormones, sitagliptin enhances glucose‑dependent insulin secretion and suppresses glucagon release, thereby reducing hepatic glucose production. The combined effect yields a dual‑targeted approach to glycemic management, as detailed by the U.S. Food and Drug Administration (FDA).

Dosage guidelines for Oxra‑S 5/50 Mg typically recommend one tablet taken orally once daily, with or without food, as prescribed by a healthcare professional. The fixed‑dose formulation delivers 5 mg of dapagliflozin and 50 mg of sitagliptin per tablet, matching the recommended therapeutic dose for most adult patients with type 2 diabetes. Adjustments may be necessary in individuals with renal impairment or those taking concomitant medications that affect glucose metabolism. It is essential to follow the prescribing clinician’s instructions regarding timing, concomitant therapy, and monitoring of renal function to achieve optimal therapeutic outcomes. MedlinePlus provides additional guidance on diabetes medication management.

Like all pharmaceutical agents, Oxra‑S may be associated with adverse effects. Common side effects include genital mycobacterial infections, urinary tract infections, and mild gastrointestinal disturbances such as nausea or abdominal discomfort. Rare but serious adverse events can involve ketoacidosis, severe renal dysfunction, or hypersensitivity reactions. Patients should be advised to monitor for symptoms such as persistent fatigue, unusual thirst, or changes in urinary patterns, and to report any concerning signs to their physician promptly. Regular laboratory assessments, including kidney function tests, are recommended during long‑term therapy.

Warnings and precautions associated with Oxra‑S 5/50 Mg necessitate careful patient selection and ongoing monitoring. The medication is contraindicated in patients with a history of hypersensitivity to dapagliflozin, sitagliptin, or any component of the formulation. Caution is advised in individuals with established chronic kidney disease, particularly those with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m², as well as in patients with a history of diabetic ketoacidosis. Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia, requiring dose adjustments. Pregnant or lactating women should avoid this medication unless explicitly directed by a qualified healthcare provider.

Frequently Asked Questions

1. What is the recommended starting dose of Oxra‑S? The usual starting dose is one tablet taken once daily, providing 5 mg dapagliflozin and 50 mg sitagliptin. Dosage should be individualized based on patient characteristics and physician assessment.
2. Can Oxra‑S be used in patients with kidney disease? Use is recommended only when the estimated glomerular filtration rate (eGFR) is above 45 mL/min/1.73 m². In patients with more advanced kidney impairment, the benefits may be limited and safety data are insufficient.
3. How does Oxra‑S differ from other diabetes pills? Unlike single‑agent therapies, Oxra‑S combines SGLT‑2 and DPP‑4 inhibition, offering complementary mechanisms that improve glycemic control, support weight management, and reduce cardiovascular risk without a high hypoglycemia profile.
4. What should I do if I miss a dose? If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed; doubling doses is not recommended.
5. Are there dietary restrictions while taking Oxra‑S? No specific dietary restrictions are required, but patients should maintain a balanced diet and avoid excessive alcohol consumption, which can affect glucose control and increase the risk of side effects.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)